Compare Bristol-Myers Squibb Co (BMY) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.68 (market cap $129.94B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.47. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| BMY | KOLD | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $65.89 | $49.39 |
52-Week Low | $42.60 | $13.58 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
KOLD trades at $28.035, down 2.11% today, with technical indicators showing a bullish bias despite recent weakness. The stock faces strong resistance at $29-$30 levels while finding support at $28. Natural gas market volatility continues to drive price action, with weather forecasts and LNG export flows being key near-term catalysts. Recent news highlights steady natural gas futures trading amid mixed demand signals.
The outlook remains tactical given KOLD's leveraged exposure to natural gas price movements. Upside potential exists if weather-driven demand strengthens, but risks include production increases and storage levels. Investors should monitor EIA storage reports and global LNG demand trends for directional cues in this volatile energy sector ETF.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
